Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

alfasan nederland b.v. - megestrolacetaat - tablet - megestrolacetaat 5 mg/stuk, - megestrol - katten

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ecuphar n.v. - allantoine; levertraan; perubalsem - zalf - cod-liver oil ointments

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ecuphar n.v. - allantoine; levertraan; perubalsem - huidspray, oplossing - cod-liver oil ointments

Europese Unie - Nederlands - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - andere dermatologische preparaten - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatitis, atopic - andere dermatologische preparaten - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. voorkomende vier of meer keer per jaar) die last hebben gehad van een eerste reactie op een maximum van zes weken een behandeling van tweemaal daags tacrolimus zalf (laesies gewist, bijna gewist of licht aangetast).

Europese Unie - Nederlands - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - andere dermatologische preparaten - behandeling van matige tot ernstige atopische dermatitis bij volwassenen die niet adequaat reageren op of niet verdragen worden door conventionele therapieën zoals lokale corticosteroïden. behandeling van matige tot ernstige atopische dermatitis bij kinderen (van 2 jaar en ouder) die niet adequaat hebben gereageerd op conventionele therapieën zoals lokale corticosteroïden. het onderhoud behandeling van matige tot ernstige atopische dermatitis voor de preventie van fakkels en de verlenging van flare-vrije intervallen bij patiënten ervaren een hoge frequentie van exacerbaties van de ziekte (ik. 4 of meer keer per jaar voorkomend) die een initiële respons hadden op een behandeling van maximaal 6 weken tweemaal daags tacrolimuszalf (laesies geklaard, bijna geruimd of licht aangetast).

Europese Unie - Nederlands - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cheplapharm arzneimittel gmbh - hydrocortisonbutyraat 1 mg/g - crème - 0,1 % - hydrocortisonbutyraat 1 mg/g - hydrocortisone butyrate

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cheplapharm arzneimittel gmbh - hydrocortisonbutyraat 1 mg/g - emulsie voor cutaan gebruik - 0,1 % - hydrocortisonbutyraat 1 mg/g - hydrocortisone butyrate

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cheplapharm arzneimittel gmbh - hydrocortisonbutyraat 1 mg/g - crème - 0,1 % - hydrocortisonbutyraat 1 mg/g - hydrocortisone butyrate